<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC 2025 20_9-10_239</article-id>
<article-id pub-id-type="doi">10.15836/ccar2025.239</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
<subj-group subj-group-type="subheading"><subject>Chronic Heart Failure</subject></subj-group>
</article-categories>
<title-group>
<article-title>Targeting maximal doses of beta-blockers in patients with heart failure with reduced ejection fraction and cardiac implantable electronic devices &#x2013; a registry-based study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-1125-8108</contrib-id><name><surname>Varga</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4550-4056</contrib-id><name><surname>Zeljkovi&#x0107;</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1428-3940</contrib-id><name><surname>&#x0160;aler</surname><given-names>Fran</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2637-9691</contrib-id><name><surname>Jurin</surname><given-names>Ivana</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>General Hospital &#x201C;Dr. Ivo Pedi&#x0161;i&#x0107;&#x201D; Sisak, Sisak</institution>, <country country="hr">Croatia</country></aff>
<aff id="aff2"><label>2</label><institution>Dubrava University Hospital</institution>, <addr-line>Zagreb</addr-line>, <country country="hr">Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Sara Varga, Op&#x0107;a bolnica &#x201E;Ivo Pedi&#x0161;i&#x0107;&#x201C;, Ul. Josipa Jurja Strossmayera 59, HR-44000 Sisak, Croatia. / Phone: +385-95-3606-461 / E-mail: <email xlink:href="sara.varga95@yahoo.com">sara.varga95@yahoo.com</email></corresp></author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>10</month><year>2025</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>10</month><year>2025</year></pub-date>
<volume>20</volume>
<issue>9-10</issue>
<fpage>239</fpage>
<lpage>239</lpage>
<history>
<date date-type="received"><day>25</day><month>09</month><year>2025</year></date>
<date><day>06</day><month>10</month><year>2025</year></date>
</history>
<permissions>
<copyright-statement>Croatian Cardiac Society</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>beta-blockers</kwd><kwd>cardiac implantable electronic devices</kwd><kwd>heart failure</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction</bold>: Cardiac implantable electronic devices (CIEDs), including implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy devices (CRTs), alongside optimal medical therapy (OMT), have been a cornerstone of treatment of heart failure with reduced ejection fraction (HFrEF) (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>). Up-titration of OMT, which includes beta-blockers (BB), is an irreplaceable step in treatment and prevention of sudden cardiac death SCD (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>). However, previous studies have shown that HFrEF patients often fail to reach target doses of OMT (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>). This study aimed to assess whether patients with ICDs and CRTs reach maximal doses of BB.</p>
<p><bold>Patients and Methods</bold>: This was an observational, registry-based study that included patients with HFrEF who had ICD or CRT implanted in our institution from January 2021 to September 2024. Data was extracted from the CaRD registry (NCT06090591).</p>
<p><bold>Results:</bold> This registry-based study included 166 patients with a median age of 64 (IQR 59-68), 81% male. All patients had BB prescribed, most often bisoprolol (74% and 59% in the ICD and CRT groups, respectively), followed by carvedilol in the ICD group (10%) and nebivolol in the CRT group (17%). Maximal doses of BB were reached in only 13% of patients prior to ICD implantation and in 12% of patients before CRT implantation. After the implantation of CIEDs, up-titration of BBs to maximal doses has not improved significantly (13 vs. 16% patients in the ICD group, p=0.206; 12 vs. 22% of patients in the CRT group, p=1.404). Most common reasons for lack of up-titration of BBs were clinician inertia (44% of patients in the ICD group and 35% of patients in the CRT group) and intolerance of higher doses (36% of patients with ICD and 38% of patients with CRTs), mostly due to arterial hypotension. In only 4% of patients in both groups, the maximal dose of BBs was not reached due to patient non-adherence.</p>
<p><bold>Conclusion</bold>: Our findings highlight the need for continuing efforts in titrating BBs to their target doses, especially in order to minimize clinician inertia.</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonagh</surname><given-names>TA</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Adamo</surname><given-names>M</given-names></name><name><surname>Gardner</surname><given-names>RS</given-names></name><name><surname>Baumbach</surname><given-names>A</given-names></name><name><surname>B&#x00F6;hm</surname><given-names>M</given-names></name><etal/><collab>ESC Scientific Document Group</collab></person-group>. <article-title>2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.</article-title> <source>Eur Heart J</source>. <year>2021</year> September 21;<volume>42</volume>(<issue>36</issue>):<fpage>3599</fpage>&#x2013;<lpage>726</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehab368</pub-id><pub-id pub-id-type="pmid">34447992</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glikson</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>JC</given-names></name><name><surname>Kronborg</surname><given-names>MB</given-names></name><name><surname>Michowitz</surname><given-names>Y</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Barbash</surname><given-names>IM</given-names></name><etal/><collab>ESC Scientific Document Group</collab></person-group>. <article-title>2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.</article-title> <source>Eur Heart J</source>. <year>2021</year> September 14;<volume>42</volume>(<issue>35</issue>):<fpage>3427</fpage>&#x2013;<lpage>520</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehab364</pub-id><pub-id pub-id-type="pmid">34455430</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rode</surname><given-names>F</given-names></name><name><surname>Pavlovi&#x0107;</surname><given-names>N</given-names></name><name><surname>Jordan</surname><given-names>A</given-names></name><name><surname>Radi&#x0107;</surname><given-names>M</given-names></name><name><surname>Lisi&#x010D;i&#x0107;</surname><given-names>A</given-names></name><name><surname>Tomi&#x0107;</surname><given-names>SS</given-names></name><etal/></person-group> <article-title>The use of beta-blockers for heart failure with reduced ejection fraction in the era of SGLT2 inhibitors - are we still afraid to up-titrate?</article-title> <source>Heart Vessels</source>. <year>2025</year> September;<volume>40</volume>(<issue>9</issue>):<fpage>797</fpage>&#x2013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1007/s00380-025-02525-7</pub-id><pub-id pub-id-type="pmid">39934336</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
